Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy

This study tests a radioactive drug called Lu-177-PSMA-617 — given before surgery — in men with high-risk localized prostate cancer. PSMA is a protein found on prostate cancer cells, and this drug delivers targeted radiation directly to those cells. The hope is that treating the cancer before surgery will improve outcomes after the prostate is removed. **You may be eligible if...** - You are 18 or older - You have prostate cancer confirmed by biopsy, with a Gleason score of 8 or higher (a measure of how aggressive the cancer is) - A special PSMA PET/CT scan shows strong PSMA expression in your prostate - You have a life expectancy of more than 10 years - You are willing and able to undergo surgery **You may NOT be eligible if...** - Your PSMA scan does not show adequate expression on the prostate - You have cancer spread to distant sites beyond the pelvis on PET imaging - You have conditions making surgery or the radioactive drug unsafe Talk to your doctor to see if this trial is right for you.